Key result
Device-detected atrial fibrillation in heart failure patients treated with cardiac resynchronization therapy was associated with a higher risk of heart failure hospitalization and lower rates of optimal biventricular pacing compared to patients without atrial fibrillation.
Why the study?
AF can interfere with adequate biventricular pacing and reduce CRT benefits, but the effect of device-detected AF on clinical outcomes and optimal pacing required investigation.
Does device-detected atrial fibrillation reduce optimal biventricular pacing and worsen clinical outcomes in heart failure patients treated with cardiac resynchronization therapy?
Cohort (n=174)
No
Does device-detected atrial fibrillation reduce optimal biventricular pacing and worsen clinical outcomes in heart failure patients treated with cardiac resynchronization therapy?
In heart failure patients receiving cardiac resynchronization therapy, incident device-detected atrial fibrillation significantly reduces the likelihood of achieving optimal biventricular pacing and is associated with worse clinical outcomes.
Answers are grounded in this paper and cite their sources.
Device-detected AF may warrant closer monitoring in CRT patients; leaves open whether targeted interventions improve pacing and outcomes.
BACKGROUND AND OBJECTIVES: Atrial fibrillation (AF) is associated with decreased cardiac resynchronization therapy (CRT) benefits compared to sinus rhythm (SR). Effective biventricular (BiV) pacing is a determinant of CRT success, but AF can interfere with adequate BiV pacing and affect clinical outcomes. We investigated the effect of device-detected AF on clinical outcomes and optimal BiV pacing in patients with heart failure (HF) treated with CRT. METHODS: We retrospectively analyzed 174 patients who underwent CRT implantation between 2012 and 2019 at a tertiary center. The optimal BiV pacing percentage was defined as ≥98%. Device-detected AF was defined as an atrial high-rate episode ≥180 beats per minute lasting more than 6 minutes during the follow-up period. We stratified the patients without preexisting AF at pre-implantation into device-detected AF and no-AF groups. RESULTS: A total of 120 patients did not show preexisting AF at pre-implantation, and 54 had AF. Among these 120 patients, 19 (15.8%) showed device-detected AF during a median follow-up of 25.1 months. The proportion of optimal BiV pacing was significantly lower in the device-detected AF group than in the no-AF group (42.1% vs. 75.2%, p=0.009). The device-detected AF group had a higher incidence of HF hospitalization, cardiovascular death, and all-cause death than the no-AF group. The device-detected AF and previous AF groups showed no significant differences regarding the percentage of BiV pacing and clinical outcomes. CONCLUSIONS: For HF patients implanted with CRT, device-detected AF was associated with lower optimal BiV pacing and worse clinical outcomes than no-AF.
No takes yet. Share an insight, caveat, or question.
Yoon et al. (2023) conducted a cohort in Heart failure with reduced ejection fraction (n=174). Device-detected atrial fibrillation vs. No atrial fibrillation was evaluated on Heart failure hospitalization (HR 3.05, 95% CI 1.26-7.35, p=0.013). Device-detected atrial fibrillation in heart failure patients treated with cardiac resynchronization therapy was associated with a higher risk of heart failure hospitalization and lower rates of optimal biventricular pacing compared to patients without atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: